Shigella vaccine safety study for healthy adults
Part of Digestive system, Infections clinical trials.
This Phase 1 study tests a Shigella (gut infection) vaccine and additives to see how safe they are in healthy adults. If you qualify, you may help researchers understand whether the vaccine triggers any unwanted immune or stomach side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 50 years old when you get the vaccine
- Be able to attend all study visits and complete all study procedures
- Have a negative stool PCR test for Shigella (a stool lab test)
- Be willing to give written informed consent before any study procedures
- If you can become pregnant: have a negative pregnancy test and use reliable birth control during the study and for a few months after
- Avoid certain medicines and situations that could interfere with safety or results
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study gives a carefully measured dose of Shigella sonnei to healthy adults to learn about the infection’s safety and how the body responds. It may help researchers build safer future tests or treatments, but it requires a hospital stay and many follow-up visits.
This trial tests a new Shigella vaccine in healthy adults to see if it is safe and creates a good immune response. It is a first-in-human study, meaning this is the first time the vaccine is given to people.
This trial tests a new vaccine called IP-QSV to see if it is safe and creates an immune response against Shigella bacteria, a common cause of diarrhea. It is for healthy adults, adolescents, children, and infants.
This trial tests an oral vaccine designed to protect against two common causes of severe diarrhea: shigella and ETEC bacteria. Healthy adults aged 18 to 50 will receive the vaccine and later be exposed to the bacteria to see if it works.
This study checks how long the altSonflex1-2-3 Shigella vaccine protects children, by looking at children who already received it in earlier studies about a year ago.
This trial tests a new vaccine to prevent urinary tract infections (UTIs). It first checks safety and immune response in healthy adults, then in women with recent E. coli UTIs. The goal is to see if the vaccine can reduce future infections.
Hear when a new Shigellosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.